Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUCCOLAM oromucosal solution special drug use surveillance
jRCT2031210712Recruiting
- Sponsor
- Clinigen
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Buccolam in epilepsy and nonconvulsive status epilepticus (NCSE), sponsored by Clinigen. Primary endpoints: Number of participants with at least one treatment-emergent adverse event (TEAE), Number of participants with serious adverse events and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
Buccolam
03
Conditions
epilepsynonconvulsive status epilepticus (NCSE)
Beyond the preview
Go deeper on jRCT2031210712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210712.